The firm, which makes both neurogenetic and oncology diagnostics, also provided updates on its market strategies and menu outlook.
University of Pennsylvania researchers found that patients with autism had a greater mutational burden in essential genes than their unaffected siblings.
The company plans to release its first product in this area, a blood-based proteomic diagnostic for epilepsy, as a laboratory-developed test next year.
The study, which is still ongoing, also provided support for a separate Phase 2/3 trial of a targeted treatment for the neurodevelopmental disorder.
The international team of researchers also examined the genetic ties between personality traits and psychiatric disorders.
The test, named EvoScore START, measures a panel of blood-based protein biomarkers to distinguish between epileptic seizures and other similar events.
The two firms are collaborating on a system to share genotypic, phenotypic, and treatment outcomes data with physicians on a mobile-device network.
Using CNV profiles for more than 40,000 individuals with or without schizophrenia, researchers got a refined look at gains and losses linked to the condition.
The findings run counter to the traditional understanding of tau's role in Alzheimer's, which holds that modified forms of the protein help drive the disease.
Using brain samples from individuals with or without autism spectrum disorder, researchers identified H3K27ac histone acetylation marks associated with ASD.
The firm is building an antibody-based immune system-related protein biomarker test for stroke diagnosis in both community and academic hospitals.
The institute has selected the firm's RNA-seq library preparation kits for use in gene expression profiling in single-cell analysis of brain cells.
Using mitochondrial sequence data for hundreds of simplex families, investigators found predicted pathogenic heteroplasmic mutations were over-represented.
The funding will support research into the roles Alzheimer's disease-associated genetic variants play in neural cell biology.
Experts pointed out the lack of clarity in professional standards and regulations when it comes to dealing with genetic variation in patient care.
A high-profile, independent committee is considering the liability issues impacting labs as genetic testing increasingly becomes integrated into patient care.
An exome-wide association study drew attention to a rare variant in TM2D3 that is more common among people of Icelandic heritage.
Researchers from the University of Texas at Dallas have designed a modular, virally-delivered, doxycycline-induced CRISPR/Cas9 system.
ImmunArray will use Quanterix's Simoa single-molecule array technology for biomarker analysis, with the potential to enrich its diagnostic panels.
By focusing on sequences that have diverged rapidly in humans, researchers identified regulatory sequences suspected of affecting neural processes.
Vivek Murthy is no longer the surgeon general of the US, the Associated Press reports.
People around the globe took to the streets to support science — some with signs.
Parents who learn of their increased genetic risk of disease also contend with telling their children about theirs, the New York Times writes.
In PLOS this week: loci linked to body mass index measurements, long non-coding RNA expression and urothelial carcinoma prognosis, and more.